DOI: 10.1007/s00259-018-4192-zPages: 1-10

Role of FDG PET/CT in monitoring treatment response in patients with invasive fungal infections

1. University Medical Center Groningen, Medical Imaging Center, Departments of Nuclear Medicine and Molecular Imaging and Radiology, University of Groningen

2. University of Pretoria, Department of Nuclear Medicine, Steve Biko Academic Hospital

3. Korle Bu Teaching Hospital, Nuclear Medicine Unit, National Centre for Radiotherapy and Nuclear Medicine

4. University Medical Center Groningen, Department of Internal Medicine, Division of Hematology, University of Groningen

5. University Medical Center Groningen, Department of Psychiatry, University of Groningen

6. University Medical Center Utrecht, and Utrecht University, Department of Radiology and Nuclear Medicine

Correspondence to:
Alfred O. Ankrah
Tel: +31 649855277
Email: a.o.ankrah@umcg.nl

Close

Abstract

Introduction

Invasive fungal infections (IFIs) occur mostly in immunosuppressed patients and can be life-threatening. Inadequate treatment is associated with high morbidity and mortality. We examined the role of 2-fluorodeoxyglucose positron emission tomography integrated with CT (FDG-PET/CT) in monitoring IFIs and therapy decision-making, and evaluated the role of baseline metabolic parameters in predicting the metabolic response.

Methods

All patients between October 2009 and March 2018, diagnosed with IFIs, treated with antifungal drugs, and who underwent FDG-PET/CT at baseline and at one or more timepoints during treatment were retrospectively included. The electronic patient files were reviewed for pathology, microbiology, and laboratory findings. All FDG-PET/CT scans were performed according to standardized European Association of Nuclear Medicine/EANM Research Limited (EANM/EARL) protocols. For each scan, the global total lesion glycolysis (TLG) and metabolic volume (MV), highest maximum standardized uptake value (SUVmax), and peak standardized uptake value (SUVpeak) were determined. The role of FDG-PET/CT on monitoring antifungal therapy was assessed by looking at the clinical decision made as result of the scan. Furthermore, the added value of the baseline metabolic parameters in predicting metabolic response to the antifungal treatment was evaluated.

Results

Twenty-eight patients with in total 98 FDG-PET/CT scans were included with a mean age of 43 ± 22 years. FDG-PET/CT altered management in 14 out of the 28 patients (50%). At the final FDG-PET/CT scan, 19 (68%) had a complete metabolic response (CMR), seven a partial response and two patients were defined as having progressive disease. Using receiver operative analysis, the cut-off value, sensitivity, specificity, and significance for the baseline TLG and MV to discriminate patients with CMR were 160, 94%, 100%, p < 0.001 and 60, 84%, 75%, p = 0.001 respectively.

Conclusion

FDG-PET/CT is useful in the monitoring of IFIs resulting in management therapy change in half of the patients. Baseline TLG and MV were found to be able to predict the metabolic response to antifungal treatment.

This article is freely available, click here to access the full text/PDF

  • Accepted: Oct 8, 2018
  • Online: Oct 21, 2018

Article Tools

eanm
EJNMMI Ad